European Biopharma Selects IntraLinks to Streamline Clinical Trial Information Exchange

IntraLinks

® (NYSE: IL), a global technology provider of inter-enterprise content management and collaboration solutions, announced that

Actelion Pharmaceuticals Ltd

, an Allschwil/Basel, Switzerland headquartered biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments to serve unmet medical needs, has selected IntraLinks Connect℠ to streamline its documentation exchange during clinical trials.

Prior to engaging IntraLinks, Actelion relied on traditional courier services to facilitate the exchange of sensitive clinical trial documentation between sponsors and participants, resulting in excessive shipping costs and manual processes for tracking and other activities.

To streamline its documentation process and gain efficiency for themselves and their investigators, Actelion chose IntraLinks Connect to provide central clinical trial portals to facilitate the more secure, compliant auditable exchange of site feasibility, study start up, study conduct and study close-out documentation.

IntraLinks Connect’s security, detailed reporting, workflows, and analytics, together with IntraLinks’ knowledgeable professional service support convinced Actelion that IntraLinks provided the best fit to its requirements. “Whilst working with IntraLinks we can see the maturity of its technology and the commitment of the team to support Actelion moving forward in this area,” said Christine Schwenninger, Head of Global Clinical Monitoring, Actelion. “We are looking forward to working closely together with IntraLinks in the coming years.”

“Actelion’s engagement of IntraLinks demonstrates the growing demand for secure information exchange within the clinical trial process,” says Andy Watson, VP of life sciences EMA at IntraLinks. “IntraLinks Connect will provide Actelion greater efficiency, traceability, and security to improve communication, collaboration, and document exchange between everyone involved in the clinical trial.”